Nemeth Krisztian, Mezey Eva
NATIONAL INSTITUTES OF HEALTH; MEDICAL COLLEGE OF WISCONSIN.
NATIONAL INSTITUTES OF HEALTH;
Blood. 2016 Feb 11;127(6):670-2. doi: 10.1182/blood-2015-12-686626.
In this issue of , Garcia-Montero et al reported that in nearly 30% of patients with indolent systemic mastocytosis (SM), the characteristic c-kit mutation D816V, is not restricted to mast cells, but may also be found in bone marrow (BM)–derived mesenchymal stem cells (MSCs), also known as BM stromal cells (BMSCs). Thus, the notion that mastocytosis is a disease driven exclusively by mutations in blood cells, especially mast cells, has now been challenged.
在本期杂志中，加西亚 - 蒙特罗等人报告称，在近30%的惰性系统性肥大细胞增多症（SM）患者中，特征性的c-kit突变D816V不仅限于肥大细胞，还可能在骨髓（BM）来源的间充质干细胞（MSC）中发现，间充质干细胞也被称为骨髓基质细胞（BMSC）。因此，肥大细胞增多症是一种仅由血细胞尤其是肥大细胞中的突变驱动的疾病这一观念现在受到了挑战。
